Open AccessThe pathway to secondary prevention of Alzheimer's disease
Author(s) -
McDade Eric,
Bednar Martin M.,
Brashear H. Robert,
Miller David S.,
Maruff Paul,
Randolph Christopher,
Ismail Zahinoor,
Carrillo Maria C.,
Weber Christopher J.,
Bain Lisa J.,
Hake Ann Marie
Publication year - 2020
Publication title -
alzheimer's and dementia: translational research and clinical interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.49
H-Index - 30
ISSN - 2352-8737
DOI - 10.1002/trc2.12069
Subject(s) - secondary prevention , disease , clinical trial , medicine , drug development , alzheimer's disease , psychology , drug , psychiatry , pathology
Alzheimer's disease (AD) is a continuum consisting of a preclinical stage that occurs decades before symptoms appear. As researchers make advances in investigating the continuum, the importance of developing drugs for secondary prevention is garnering increased discussion. For efficacious drug development for secondary prevention it is important to define what are the earliest biological stages of AD. The Alzheimer's Association Research Roundtable convened November 27 to 28, 2018 to focus on pre‐clinical AD. This review will address the biological approach to defining pre‐clinical AD, detection, identification of at‐risk individuals, and lessons learned from trials such as A4 and TOMMORROW.